ArticleBMJ open2017
Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre.
Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Influence of PAI-1 gene polymorphism on the effectiveness of tezepelumab in individuals with severe asthma: a study protocol for a prospective, non-randomized, interventional, comparative trial.Journal of thoracic disease · 2026Article
- Where eye meets body part 2: uniting allergy pathways in ocular and atopic disease - T cells take the lead.Current opinion in allergy and clinical immunology · 2025Review
- Single cell analysis identifies distinct CD4 + T cells associated with the pathobiology of pediatric obesity related asthma.Scientific reports · 2025Article
- Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care.International journal of chronic obstructive pulmonary disease · 2025Article
- When patient-reported respiratory symptoms shed light on pathophysiology in adult asthma: a cross-sectional study.Scientific reports · 2024Article
- Triple Therapy De-Escalation and Withdrawal of Inhaled Corticosteroids to Dual Bronchodilator Therapy in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Bioinformatics analysis of G protein subunit gamma transduction protein 2-autophagy axis in CD11b+ dendritic cells as a potential regulator to skew airway neutrophilic inflammation in asthma endotypes.Immunity, inflammation and disease · 2024Article
- Effect of fluticasone propionate/formoterol and fluticasone furoate/vilanterol on adolescents with chronic bronchial obstruction.The journal of allergy and clinical immunology. Global · 2024Article
- Change is in the air: key questions on the 'Treatable Traits' model for chronic airway diseases in primary care.NPJ primary care respiratory medicine · 2024Review
- Predictors of change in asthma-related quality of life: a longitudinal real-life study in adult asthmatics.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Asthma inflammatory phenotypes on four continents: most asthma is non-eosinophilic.International journal of epidemiology · 2023Article
- Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease.Internal medicine (Tokyo, Japan) · 2023Article
- Development and validation of a predictive model combining patient-reported outcome measures, spirometry and exhaled nitric oxide fraction for asthma diagnosis.ERJ open research · 2023Article
- Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma.Frontiers in medicine · 2023Review
- Obesity, Insulin Resistance, and Asthma.American journal of respiratory and critical care medicine · 2022Article
- Clinical Characteristics and Management Strategies for Adult Obese Asthma Patients.Journal of asthma and allergy · 2022Review
- Critical evaluation of asthma biomarkers in clinical practice.Frontiers in medicine · 2022Review
- Asthma in elite athletes - do they have Type 2 or non-Type 2 disease? A new insight on the endotypes among elite athletes.Frontiers in allergy · 2022Review
- Treatment Response Biomarkers in Asthma and COPD.Diagnostics (Basel, Switzerland) · 2021Review
- Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD.Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe impact of inhaled corticosteroids (ICS) on eosinophilic inflammation in asthma is well established, but their effect in a real-life setting has not been extensively studied. Our purpose was to investigate the effect of ICS on airway and systemic inflammation as well as on clinical outcomes in patients with asthma from clinical practice. DESIGN, SETTING AND
participantsWe conducted a retrospective analysis on asthmatics from a secondary care centre in whom ICS were initiated/increased (n=101), stopped/decreased (n=60) or remained stable (n=63, used as a control group) between two visits with available sputum and blood cell counts.
resultsThe median time between both visits ranged from 1 to 2 years. Initiating or increasing ICS (median variation (IQR): 800 (400-1200) µg beclomethasone equivalent dose per day) reduced sputum eosinophils and fractional exhaled nitric oxide (P<0.0001) and to a lesser extent blood eosinophils (P<0.0001), while withdrawing or decreasing ICS (median variation (IQR): 900 (500-1200) µg beclomethasone equivalentdose per day) resulted in increased sputum eosinophils (P=0.008). No change was found in patients with a stable dose. The effectiveness of ICS in improving asthma control, quality of life, forced expiratory volume in 1 s (FEV
conclusionsOur results confirm the effectiveness of ICS on eosinophilic inflammation in real life and demonstrate that their clinical benefit seems to be restricted to eosinophilic asthmatics. Our data also support a try for stepping-down ICS in non-eosinophilic asthmatics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.